Presented today the data from the Korean CSG BR 18-2 trial of ribociclib + trastuzumab + letrozole, first line chemo free regimen for HR+Her2+ MBC #ASCO25

ORR 61%
mPFS 30.4m
DOR 11.8m
Special look at toxicity (pruritus 24%, LFTs?)

Abstract 1016
Halls D2 3:15 PM May 30
#bcsm

Dose optimization of KAT6A inhibitor PA-07248144 will be presented today #ASCO25

Based on PK, tox, and activity (ORR 37%, cBR 56%, mPFS 10.7m), the 5 mg dose in combination with fulvestrant will move forward to RPh3 study in 2L HR+HER2- MBC @DFCI_BreastOnc

Hall D2 3:51 PM
Abstract 1020
#bcsm

Hope you had a safe flight. These curves are not convincing me…we need a statistician to comment. Unplanned retrospective analyses.

Dr Kaelin gave a very thought provoking talk.

He argues single agent therapies will never cure cancer due to resistance.

Our chance is cure will come with multiple non-cross resistant therapies, challenging current paradigms.

#bcsm

The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX

#MedSky #SABCS24

BWEL intervention with diet and weight loss is able to improve:
✅metabolic biomarkers
✅insulin resistance
✅ stress biomarkers
BWEL study presented by Dr. Jennifer Ligibel. Looking forward to future data with improved breast cancer outcomes. @dfcibreastonc.bsky.social #SABCS24

Phase I clinical trials: it is important to get the dose as right as possible prior to phase III clinical trials. @fda.gov project OPTIMUS focus on totality of data for improved dose decision making:
- minimize toxicity
- enhance efficacy
- improve outcome for patients
#SABCS24 #clinicaltrials

Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social

Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24

The largest oncology conference in Asia with over 4,000 participants is about to start. #ESMOAsia24 Singapore

Strong showing by #OhioState #BreastMedOnc for 100 top oncoinfluencers @stoverlab.bsky.social @quirogad.bsky.social Dr Arya Roy. Honored to be included and looking forward to this list for 🦋 next year! oncodaily.com/positive/bre...

let's hope #BlueSky will not be for sale

Single cell analysis of normal breast tissue-BRCA1/BRCA2 carriers contained a small percentage of cells with extreme aneuploidy, featuring loss of TP53, BRCA1/BRCA2 LOH and multiple breast cancer-associated CNAs, likely precursors to clonally expanded tumor genomes pubmed.ncbi.nlm.nih.gov/39567747/

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!

There is not enough evidence for poor performance of cdk4/6i (abema in MonarchE) in patients with BRCA pathogenic mutations. These patients still
deserve adj cdk4/6i if they meet criteria. Nadia Harbeck discussing this topic in Bogota 🇨🇴

Nobel Prize-winning cancer researcher to deliver keynote address at #SABCS2024 Our next phase 1 clinical trial based on his lab research entering pipeline in our CCTI (EDC) program at Dana-Farber - stay tuned! www.sabcsmeetingnews.org/nobel-prize-...

When you open #bluesky and don’t see spaceX as your first feed 💙🦋 #oncsky relieved by H&E pathology slide @viveksubbiah.bsky.social

This looks very much like twitter in 2010! 😅 goodbye X